Apnimed Restates Q2 2026 Financials After SASS Gain Misclassification
APMD sits 22% above its 52-week low of $13.88.
Summary
Apnimed's audit committee said its Q2 2026 financials can no longer be relied on after the $85.4 million SASS gain was misclassified as continuing rather than discontinued operations. The restatement is a reclassification with no change to net income, cash or equity, but it follows a previously disclosed material weakness in internal controls.
Key Events · Legal and Risk Events · APMD
-
Audit Committee Pulls Q2 2026 Financials
On November 13, 2026, the Audit Committee concluded that the financial statements for the three and six months ended June 30, 2026 should no longer be relied upon.
-
SASS Gain Misclassified
The $85.4 million gain on the April 6, 2026 sale of the 50% SASS stake was recorded in continuing operations instead of discontinued operations under ASC 205-20.
-
Restatement Is Reclassification Only
The correction does not change revenue, income from operations, total net income, EPS, cash, total assets, liabilities, equity or cash flows as previously reported.
-
10-Q/A Planned for Today
The company intends to file an amendment to the September 8, 2026 10-Q on November 13, 2026, revising the notes, MD&A and controls disclosures.
Analysis · APMD · Life Sciences
The Audit Committee has concluded that the June 30, 2026 financials can no longer be relied upon, because the $85.4 million gain on the SASS sale was booked in continuing operations instead of discontinued operations. Critically, the restatement does not change revenue, operating loss, total net income, EPS, cash, assets, liabilities, equity or cash flows — it is a reclassification, not a new loss. The bigger issue is credibility: this is the second accounting problem in the same quarter, coming on top of a previously disclosed material weakness in internal controls, and it lands while the company is in front of the FDA with its obstructive sleep apnea drug. Management says it has hired 5 people to shore up the accounting function and intends to file the 10-Q/A today.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APMD was trading at $16.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.4M. The 52-week trading range was $13.88 to $35.29. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.